FDA clears Galil's cryotherapy for kidney cancer:
This article was originally published in Clinica
Executive Summary
Galil Medical has received US FDA 510(k) clearance to expand the use of its minimally invasive SeedNet Gold cryotherapy system to the treatment of kidney cancer. The product, previously cleared for treating prostate cancer, uses the company's ultra-thin CryoNeedles to provide a nephron-sparing approach for ablating cancerous kidney masses, says the Yokneam, Israel firm.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.